Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Update

Athira Pharma, Inc. (NASDAQ:ATHA) was the recipient of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 1,170,000 shares, a decrease of 17.6% from the December 31st total of 1,420,000 shares. Based on an average trading volume of 4,600,000 shares, the days-to-cover ratio is currently 0.3 days. Approximately 3.3% of the shares of the company are sold short.

Institutional Trading of Athira Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. GSA Capital Partners LLP grew its position in shares of Athira Pharma by 909.8% during the 3rd quarter. GSA Capital Partners LLP now owns 397,111 shares of the company’s stock worth $177,000 after purchasing an additional 357,787 shares in the last quarter. Bristlecone Advisors LLC grew its position in Athira Pharma by 295.6% during the third quarter. Bristlecone Advisors LLC now owns 337,506 shares of the company’s stock worth $151,000 after buying an additional 252,200 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Athira Pharma by 25.5% during the second quarter. Dimensional Fund Advisors LP now owns 550,353 shares of the company’s stock worth $1,458,000 after buying an additional 111,759 shares in the last quarter. Invst LLC bought a new position in Athira Pharma during the 2nd quarter worth $68,000. Finally, XTX Topco Ltd acquired a new position in Athira Pharma in the 2nd quarter valued at $60,000. Institutional investors and hedge funds own 57.12% of the company’s stock.

Athira Pharma Trading Down 1.6 %

Shares of NASDAQ:ATHA traded down $0.01 during trading on Friday, reaching $0.53. 184,819 shares of the stock were exchanged, compared to its average volume of 177,488. Athira Pharma has a 12 month low of $0.41 and a 12 month high of $4.30. The stock has a 50-day moving average price of $0.57 and a 200-day moving average price of $1.21. The firm has a market cap of $20.31 million, a PE ratio of -0.18 and a beta of 2.99.

Athira Pharma (NASDAQ:ATHA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.05. On average, sell-side analysts expect that Athira Pharma will post -2.35 earnings per share for the current fiscal year.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.